Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future developments in therapy.

Carlos M Isales1, Jay M McDonald

  • 1Department of Orthopaedic Surgery, Medical College of Georgia, Institute of Molecular Medicine and Genetics, Augusta, Georgia 30912, USA. cisales@mcg.edu

Annals of the New York Academy of Sciences
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conditional Knockout of Indoleamine 2, 3-Dioxygenase-1 in Osteoprogenitor Cells in Mice Results in Sex-dependent Differences in Bone Mass.

Biochimie·2026
Same author

Crosstalk with bone marrow adipocytes, but not osteoblasts, drives a cortical bone resorption phenotype in female mice with adult-onset deletion of the glucocorticoid receptor in Osterix-expressing cells.

JBMR plus·2026
Same author

Validation of the adenine model of chronic kidney disease: studies on tryptophan metabolism in Sprague Dawley rats.

The Journal of endocrinology·2026
Same author

Tryptophan metabolites 3-hydroxykynurenine (3HK) and 3-hydroxyanthranilic acid (3HAA) increase oxidative stress and impair osteoblastic bone formation.

The Journal of biological chemistry·2026
Same author

Microbiota-derived indole-3-propionic acid extends lifespan in Drosophila and improves muscle and bone health in mice.

GeroScience·2026
Same author

Effects of two longevity interventions, calorie restriction and rapamycin treatment, on the kynurenine-aryl hydrocarbon receptor pathway in aging skeletal muscle.

Biochimie·2025
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

New osteoporosis drugs are emerging, driven by advances in understanding bone biology and molecular pathways. Future research must focus on improved bone quality assessment beyond bone mineral content to ensure effective osteoporosis therapies.

Area of Science:

  • Bone biology
  • Osteoporosis research
  • Pharmacology

Background:

  • Current osteoporosis treatments are being re-evaluated based on improved understanding of their mechanisms of action.
  • Advances in molecular pathways of bone formation offer new therapeutic targets.

Purpose of the Study:

  • To highlight the need for enhanced methods to assess bone quality alongside new drug development for osteoporosis.
  • To emphasize the integration of basic bone research into the rational design of osteoporosis therapies.

Main Methods:

  • Review of current understanding in bone biology and osteoporosis mechanisms.
  • Analysis of limitations in existing bone quality assessment methods like DXA.
  • Discussion on the essential protein (collagen type I) and mineral (hydroxyapatite) components of bone.

Related Experiment Videos

Main Results:

  • Increased knowledge of molecular pathways is paving the way for novel osteoporosis medications.
  • Existing methods like DXA provide a limited view of bone strength, necessitating better assessment tools.
  • Bone strength relies on both protein and mineral content, requiring comprehensive evaluation.

Conclusions:

  • Future osteoporosis drug development requires a deeper understanding of bone molecular pathways.
  • Development of new drugs must be coupled with improved methods for assessing overall bone quality.
  • Therapeutic agents should aim to enhance bone strength within a specific physiological window.